PIH50 Choosing between the promis global and eq-5d for comparative effectiveness research: are they really different?  by Runge, SK & Craig, BM
A112  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
stakeholders (including researchers, industry, academia, FDA, clinicians, and payers) 
play an important role in translation. Avalere defined four stages in the translation of 
PROs: issue identification, research, clinical practice, and implementation in quality 
and performance measurement. Literature revealed that PROs for research purposes 
must be developed, tested, and evaluated with baseline science standards in mind, 
such as psychometric soundness, rigor, validity, generalizability, and aggregatabil-
ity. PROs used in clinical practice are subject to additional criteria considering the 
science behind practicality, interoperability, and timing/mode of administration. At 
the implementation stage, there is the opportunity to define a particular outcome or 
process of care that can be assessed by a PRO. Once rigorously evaluated for scien-
tific acceptability, feasibility of data collection, and other criteria, PRO measures can 
be implemented in quality reporting or payment programs with established bench-
marks. ConClusions: Stakeholders are still ironing out the “kinks” of the develop-
ment, use, and implementation of PROs. Our conceptual framework for PRO translation 
can provide a starting point for stakeholders interested in applying best practices to 
the routine use of PROs in clinical trials and at the point of care, and as PRO measures 
become more sophisticated, in quality reporting and payment programs.
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objeCtives: To inform the design of comparative effectiveness studies (CER), a 
head-to-head psychometric comparison of the PROMIS Global and EQ-5D instru-
ments is needed. Methods: In 2013, 2289 US adults completed an online survey 
including 10 items from the PROMIS Global and 5 items from the 3 EQ-5D versions 
(EQ-5D-3L, EQ-5D-Y, and EQ-5D-5L) in random order. After testing for unidimen-
sionality between each pair of these 25 items, we conducted 3 separate exploratory 
factor analyses (EFA) between the PROMIS Global and each EQ-5D version. Next, we 
performed an item-response-theory (IRT) analysis for factors shared between the 
2 instruments. Item levels with insufficient responses (n< 40) were collapsed. The 
relative degree of information obtained by each instrument was assessed using an 
unconstrained graded response model. Results: All items were positively cor-
related (0.32 to 0.98). Regardless of EQ-5D version, EFA analyses identified 3 factors 
(eigenvalue > 1): Physical Health (PH), Mental Health (MH), and Quality of Life (QL). 
Each item uniquely loaded to a single factor after rotation. Unlike PH and MH, QL 
included only PROMIS items. At a threshold of 0.5 in standard error, the IRT analy-
ses showed similar PH information function ranges by instrument (-0.2 to 2.8 for 
EQ-5D-5L vs. -0.2 to 2.4 for PROMIS Global). However, the MH information range for 
EQ-5D-5L was substantially narrower than the range for the PROMIS Global (0.3 to 
2.4 vs. -0.8 to 2.8). ConClusions: The PROMIS Global includes 5 items that extend 
the measurement of general health beyond the 2 factors shared with the EQ-5D. 
When comparing the remaining 5 items of the PROMIS Global to the EQ-5D, the 
instruments appear to share information ranges in PH, but the PROMIS Global has 
a broader MH range than the EQ-5D. These similarities and differences are impor-
tant considerations when choosing between the PROMIS Global and EQ-5D for CER.
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objeCtives: Uterine fibroids (UF) are associated with significant reduction in 
health-related quality of life (HRQL). This cross-sectional survey examined the 
impact of UF-related symptoms on HRQL using a disease-specific instrument, the 
UFS-QoL. Methods: An online survey of US women between 18 and 54 years was 
conducted using 3 large respondent panels as a sampling frame. Data collected 
included demographics, UF prevalence, symptoms, HRQL and health-related produc-
tivity. Descriptive statistics were used to examine the impact of symptom presence, 
symptom severity, bothersomeness, and number of UF-related symptoms on multiple 
domains of HRQL. Analyses were weighted to match the population distribution of 
age, education, region, and household income of US female population. Results: 
59,411 (15.5%) of the panel members who were contacted completed the prevalence 
screener; 5,879 met inclusion criteria for survey completion. Of those, 1,397 had UF 
and no hysterectomy. Mean age was 42.8 years; 65% were white; 62% were married 
or in a civil union. Among the most common symptoms experienced in the past 4 
weeks, at least 49% rated each symptom as at least “moderate” severity and > 87% 
rated a symptom as at least “somewhat bothersome”. Mean UFS-QoL subscale scores 
were significantly (p< 0.05) worse among women who reported each UF symptom 
versus women in whom the symptom was absent. In particular, the presence of 
bleeding and also non-bleeding symptoms (pelvic pressure, low back pain, abdominal 
pain, bloating, and fatigue/weariness/anemia) was related to worse UFS-QoL subscale 
scores. Women who rated their UF symptoms as severe had significantly (p< 0.001) 
worse UFS-QoL scores versus women with mild or moderate UF symptoms. In addi-
tion, UFS-QoL subscale scores worsened as the number of UF symptoms experienced 
increased. ConClusions: HRQL among women with UF was significantly impacted 
by UF-related symptoms. A more pronounced impact was observed as the number 
and severity of symptoms increased.
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objeCtives: A predominant Health-Related Quality of Life Model (described by 
Wilson and Cleary in 1995) proposes a sequential relationship from biological and 
physiological variables to perceived health and overall quality of life. We assessed 
the extent to which disability mediates the association between mental and physi-
cal conditions with perceived health. Methods: Data come from the WHO World 
Mental Health (WMH) Surveys carried out in 22 countries worldwide (n = 51,344 
respondents, 72.0% response rate). We assessed 9 common mental disorders with 
the WHO Composite International Diagnostic Interview v3.0 (CIDI), and 10 chronic 
physical with a checklist. Perceived health (PH) in the previous 30 days was assessed 
using a numerical scale (from 0, worst, to 100, best). Disability was assessed using 
a modified WHO Disability Assessment Schedule 2.0 (WHODAS). Path analysis and 
multigroup techniques were used to estimate total effects of physical and mental 
conditions on perceived health PH and their separate direct and indirect (through 
the latent and observed WHODAS dimensions) effects. Results: 12-month preva-
lence was 14.4% for any mental and 51.4% for any physical condition. Disability was 
common and a 31.7% had problems with Role functioning, 11.4% with Mobility and 
8.3% with Stigma. Overall mean Perceived Health (PH) scores was 81. The model 
explained 36% of PH score variance and estimated a significant score decrement 
of 8.5 for individuals with a mental disorder and of -8.2 for those with a physical 
condition. Of those decrements, 73.7% (mental) and 59.0% (physical) were “indirect” 
effects (i.e., mediated by disability). Mediation importance of disability domains dif-
fered by mental and physical conditions. ConClusions: A large proportion of the 
decrement in perceived health associated with common conditions is mediated by 
disability. Disability mediation patterns are different for mental and physical condi-
tions. These data support the validity of the Health-Related Quality of Life Model.
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objeCtives: To evaluate the Health related quality of life among patients using 
complementary Alternative medicine (homeopathy) in Quetta, Pakistan. Methods: 
A cross sectional, descriptive study was undertaken among the patients visiting 
three major homeopathic clinics in Quetta City, Pakistan. Health related quality of 
life was assessed using European Quality of Life scale (EQ-5D). Descriptive analysis 
was used to elaborate patients’ demographic characteristics while inferential sta-
tistics were applied to report the association among study variables. Results: Out 
of 500 questionnaires distributed 486 were received with a response rate of 97.2%. 
Gender distribution was 264 (54.4%) males. Mean age of the study participants was 
34.05 ± 13.0 years with 334 (68.7%) married and 431 (88.7%) having urban residency. 
The mean EQ-5D descriptive score and EQ-VAS score were 0.59 ± 0.22 and 60.19 ±16.9 
respectively. ConClusions: The health related quality of life in patients using 
Homeopathy is slightly low then Health related quality of life of general population 
of Quetta. This study provides baseline assessment for the health status of patients 
using homeopathy and the results could be applied in clinical practice.
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objeCtives: Personalized medicine tests (PMT) are increasingly available in the 
healthcare marketplace. The diffusion of such technologies is in part a function of 
the collective preferences of patients, providers, and payers. The objective of our study 
was to identify the attributes of PMTs most important to patients and thus likely to 
impact individual decisions and population level adoption. Methods: We used a 
mixed methods study design to identify the attributes of PMTs that impact patient 
decision-making. We recruited patients with and without prior PMT experience to 
participate in focus groups and interviews via flyers, provider contacts, and disease 
support groups. Patients completed an attributes ranking exercise and a payment 
card scenario to estimate willingness-to-pay (WTP) for PMTs. Analysis of transcripts 
was performed using thematic coding, analysis of attribute ranking used a rank-
ordered logit model, and payment card data was conducted using interval regres-
sion. Results: We contacted 32 patients of which 20 ultimately participated (focus 
groups: 14; interviews: 6). Analysis of the attribute rankings indicated that the most 
important attributes were: 1) ability to select the appropriate treatment, 2) benefit to 
family members, and 3) quality of life after testing. The rankings for these character-
istics were all statistically significant. The average willingness-to-pay for a PMT was 
$1,528 (95%CI: $361-2,694). Patients making less than $25K/year had a statistically 
significant lower WTP ($373) compared to the population average. ConClusions: 
Patients showed a strong preference for the ability to select the appropriate treatment 
based on test results as well as the impact of test results on their family and their 
quality of life. Patients were willing to pay more than would typically be required 
in an insured population but less than the full cost of some commonly used PMTs. 
This work will ultimately be used to inform the development of a discrete choice 
experiment.
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